Pagliaro Pasqualepaolo, Belardinelli Annarita, Boko Viana, Salamon Petar, Manfroi Silvia, Tazzari Pier Luigi
Immunohaematology and Transfusion Unit, S. Orsola-Malpighi Hospital, Bologna.
Blood Transfus. 2014 Oct;12(4):458-63. doi: 10.2450/2014.0284-13. Epub 2014 Jun 5.
Assessing blood-donor haemoglobin (Hb) is a worldwide screening requirement against inappropriate donation. The pre-donation Hb (which should be at least 12.5 g/dL in women and 13.5 g/dL in men) is usually determined in capillary blood from a finger prick, using a spectrophotometer which reveals the absorbance of blood haemolysed in a microcuvette. New non-invasive methods of measuring Hb are now available.
In the first semester of 3 consecutive years three different strategies were employed to screen donors for anaemia at the moment of donation. In 2011 all whole-blood donors underwent the finger-prick method using azide-methaemoglobin: the test's negative predictive value (NPV) was determined by comparison with the sub-threshold Hb values ascertained by haemocytometry of test-tube blood drawn at the start of the donation. In 2012 the donor evaluation was based on NBM 200 occlusion spectrophotometry. The same approach was kept in 2013, but a haemocytometry test was added on a pre-donation venous sample drawn from donors who, though fit to donate, had previous critical Hb values in their clinical records.
In 2011, the NPV (in 3,856 donors) was 86% for women and 95% for men; in 2012 (3,966 donors), the values were 85% and 95%, respectively, and in 2013 (3,995 donors) they were 91% and 97%, respectively. Fisher's test for contingency tables revealed no statistically significant differences between 2011 and 2012, but the 2013 results were a significant improvement.
Measuring Hb by finger prick is not wholly satisfactory since, above all in women, the result of this screening may subsequently be belied by the haemocytometry finding of an unacceptable Hb value. Using a non-invasive method does not diminish the selective efficiency. In women, in particular, adding a haemocytometric test on a venous sample significantly improves donor selection and avoids the risk of inappropriate donation or blood-letting.
评估献血者血红蛋白(Hb)是全球范围内针对不当献血的一项筛查要求。献血前的血红蛋白水平(女性至少应为12.5g/dL,男性至少应为13.5g/dL)通常通过手指采血获取毛细血管血样,使用分光光度计测定,该仪器可显示微量比色皿中溶血血液的吸光度。目前已有新的无创测量血红蛋白的方法。
在连续三年的第一学期,采用了三种不同策略在献血时筛查献血者是否贫血。2011年,所有全血献血者均采用叠氮高铁血红蛋白手指采血法:通过与献血开始时采集的试管血血细胞计数法确定的低于阈值的血红蛋白值进行比较,来确定该检测的阴性预测值(NPV)。2012年,献血者评估基于NBM 200闭塞分光光度法。2013年采用了相同方法,但对临床记录中有临界血红蛋白值、虽适合献血但此前有过此类情况的献血者,在献血前静脉采血样本上增加了血细胞计数检测。
在2011年(3856名献血者),女性的NPV为86%,男性为95%;2012年(3966名献血者),相应值分别为85%和95%;2013年(3995名献血者),分别为91%和97%。列联表的费舍尔检验显示,2011年和2012年之间无统计学显著差异,但2013年的结果有显著改善。
通过手指采血测量血红蛋白并不完全令人满意,因为尤其是女性,这种筛查结果随后可能会被血细胞计数法发现的不可接受的血红蛋白值所推翻。使用无创方法并不会降低选择效率。特别是对于女性,在静脉血样本上增加血细胞计数检测可显著改善献血者选择,并避免不当献血或放血的风险。